Adrabetadex is under clinical development by Mandos and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease). According to GlobalData, Phase II drugs for Coronary Artery Disease (CAD) (Ischemic Heart Disease) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Adrabetadex’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adrabetadex is under development for the treatment of Niemann-Pick disease type C1 (NPC1), coronary artery disease and atherosclerosis. VTS-270 administered into the cerebrospinal fluid through an intrathecal, intravenous infusion and oral route. It is a formulation of (2-hydroxypropyl)-beta-cyclodextrin).
For a complete picture of Adrabetadex’s drug-specific PTSR and LoA scores, buy the report here.